EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Epigenetic regulators are emerging as key cancer therapeutic targets.
• Enhancer of zeste homolog 2 (EZH2), a component of Polycomb repressive complex 2 (PRC2), typically functions in gene silencing through histone methylation.
• Castration-resistant prostate cancer (CRPC) presents a significant therapeutic challenge.

Purpose of the Study:

• To investigate the oncogenic role of EZH2 in castration-resistant prostate cancer.
• To determine if EZH2's function in CRPC relies on its canonical transcriptional repressor activity.
• To explore novel therapeutic strategies targeting EZH2 in advanced prostate cancer.

Main Methods:

• Analysis of EZH2 function in castration-resistant prostate cancer cell lines.
• Investigating the interaction of EZH2 with transcription factors, including the androgen receptor.
• Assessing the impact of EZH2 phosphorylation and methyltransferase activity on its oncogenic function.

Main Results:

• EZH2 promotes castration-resistant prostate cancer progression through a mechanism independent of its transcriptional repressor function.
• EZH2 acts as a coactivator for key transcription factors, notably the androgen receptor.
• This coactivator function is contingent upon EZH2 phosphorylation and requires an intact methyltransferase domain.

Conclusions:

• The oncogenic activity of EZH2 in CRPC involves a non-canonical role as a coactivator.
• Targeting the non-PRC2, coactivator function of EZH2 presents a promising therapeutic avenue.
• This approach may be effective for treating metastatic, hormone-refractory prostate cancer.